nach oben

Current Gastroenterology Reports

Erschienen in:

21.08.2023

Current Status of Living Donor Liver Transplantation: Impact, Advantages, and Challenges

verfasst von: Hao Liu, Eishan Ashwat, Abhinav Humar

Erschienen in: Current Gastroenterology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of this Review

This review provides an overview of the current status of Living Donor Liver Transplant (LDLT). It discusses the impact of LDLT on waitlist and post-transplantation outcomes, highlighting the technical challenges and unique advantages of LDLT.

Recent Findings

Recent findings show that LDLT offers several theoretical advantages over deceased donor liver transplant, including shorter wait times, better graft quality, and improved post-transplant outcomes. Non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are emerging as the leading indications for adult LDLT in the US. LDLT demonstrates comparable or better overall survival rates and organ-specific outcomes compared to deceased donor transplants. However, challenges exist, including donor and recipient risks such as biliary complications and small-for-size syndrome. Ongoing research focuses on refining surgical techniques, exploring minimally invasive approaches, utilizing predetermined donors to modulate the recipient's immune system, and ensuring ethical practices.

Summary

LDLT is a valuable solution for patients with end-stage liver failure or disorders requiring transplantation. It offers advantages such as shorter wait times as well as improved waitlist and post-transplant outcomes. Continued research and advancements in LDLT will benefit patients in need of liver transplantation.

Nur mit Berechtigung zugänglich

Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet. 1989;2(8661):497.PubMedCrossRef

Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322(21):1505–7.PubMedCrossRef

Hashikura Y, Makuuchi M, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, Kiyosawa K, Ichida T. Successful living-related partial liver transplantation to an adult patient. Lancet. 1994;343(8907):1233–4.PubMedCrossRef

Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, Chan JK, Ng IO, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg. 1997;226(3):261–9 (discussion 269-70).PubMedPubMedCentralCrossRef

Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R, Trouillot TE, Mandell MS, Steinberg TG, Kam I. Adult living donor liver transplantation using a right hepatic lobe. Transplantation. 1998;66(10):1313–6.PubMedCrossRef

Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, Schnellinger EM, Handarova D, Weiss S, Cafarella M, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2021 annual data report: liver. Am J Transplant. 2023;23(2 Suppl 1):S178–263.PubMedCrossRef

Brown RS Jr, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, Hoofnagle JH. A survey of liver transplantation from living adult donors in the United States. N Engl J Med. 2003;348(9):818–25.PubMedCrossRef

Kwong AJ, Lai JC, Dodge JL, Roberts JP. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score. Liver Transpl. 2015;21(11):1403–9.PubMedPubMedCentralCrossRef

Nagai S, Chau LC, Schilke RE, Safwan M, Rizzari M, Collins K, Yoshida A, Abouljoud MS, Moonka D. Effects of allocating livers for transplantation based on model for end-stage liver disease-sodium scores on patient outcomes. Gastroenterology. 2018;155(5):1451-1462 e3.PubMedCrossRef

10.

Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology. 2006;43(2):345–51.PubMedCrossRef

11.•

Yoeli D, Choudhury RA, Moore HB, Jackson WE, Nydam TL, Wachs ME, Pomfret EA, Adams MA. Living donor liver transplant center volume influences waiting list survival among children listed for liver transplantation. Transplantation. 2022;106(9):1807–13. An SRTR/OPTN analysis showing that high-volume pediatric LDLT center can improve waiting list survival, whereas higher DDPLT and overall volume are associated with improved posttransplant survival.PubMedCrossRef

12.

Esmati H, van Rosmalen M, van Rheenen PF, de Boer MT, van den Berg AP, van der Doef HPJ, Rayar M, de Kleine RHJ, Porte RJ, de Meijer VE, Verkade HJ. Waitlist mortality of young patients with biliary atresia: Impact of allocation policy and living donor liver transplantation. Liver Transpl. 2023;29(2):157–63.PubMedPubMedCentralCrossRef

13.••

Jackson WE, Malamon JS, Kaplan B, Saben JL, Schold JD, Pomposelli JJ, Pomfret EA. Survival benefit of living-donor liver transplant. JAMA Surg. 2022;157(10):926–32. A case-control study involving 119,275 liver transplant candidates found that even patients with a MELD-Na score as low as 11 experienced a significant 34% reduction in mortality compared to those who remained on the waitlist. Furthermore, patients who underwent a living-donor liver transplant could expect to gain an additional 13 to 17 years of life compared to individuals who did not receive a transplant.PubMedPubMedCentralCrossRef

14.••

Lai Q, Sapisochin G, Gorgen A, Vitale A, Halazun KJ, Iesari S, Schaefer B, Bhangui P, Mennini G, Wong TCL, Uemoto S, Lin CC, Mittler J, Ikegami T, Yang Z, Frigo AC, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut JP. Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant. JAMA Surg. 2021;156(9):e213112. Having a potential live donor for liver transplantation can reduce the risk of death for patients with hepatocellular carcinoma (HCC) who are on the waiting list. This advantage is attributed to the elimination of the risk of patients dropping out from the list. The study specifically noted this benefit in centers where both living-donor liver transplant (LDLT) and deceased-donor liver transplant (DDLT) options are equally accessible.PubMedPubMedCentralCrossRef

15.

Ben-Haim M, Emre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, Schwartz ME, Miller CM. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient’s disease. Liver Transpl. 2001;7(11):948–53.PubMedCrossRef

16.

Selzner M, Kashfi A, Cattral MS, Selzner N, McGilvray ID, Greig PD, Levy GA, Renner EL, Grant DR. Live donor liver transplantation in high MELD score recipients. Ann Surg. 2010;251(1):153–7.PubMedCrossRef

17.

Chok K, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, Lo CM. Survival outcomes of right-lobe living donor liver transplantation for patients with high Model for End-stage Liver Disease scores. Hepatobiliary Pancreat Dis Int. 2013;12(3):256–62.PubMedCrossRef

18.•

Matoba D, Noda T, Kobayashi S, Sasaki K, Iwagami Y, Yamada D, Tomimaru Y, Takahashi H, Doki Y, Eguchi H. Analysis of short-term and long-term outcomes of living donor liver transplantation for patients with a high model for end-stage liver disease score. Transplant Proc. 2023;55(4):893–7. This study included 102 patients who underwent LDLT in a single center between 2005 and 2020. The patients were divided into 3 groups according to MELD score (low MELD group: ≤20 (n=68), moderate MELD group: 21-30 (n=24), and high MELD group: ≥31 (n=10)). LDLT patients with high MELD scores do not have a worse prognosis than those with low scores.PubMedCrossRef

19.•

Wong TC, Fung JY, Pang HH, Leung CK, Li HF, Sin SL, Ma KW, She BW, Dai JW, Chan AC, Cheung TT, Lo CM. Analysis of survival benefits of living versus deceased donor liver transplant in high model for end-stage liver disease and hepatorenal syndrome. Hepatology. 2021;73(6):2441–54. Implementing intention-to-treat living donor liver transplantation (ITT-LDLT) resulted in a decrease in mortality while patients were on the waitlist and facilitated earlier access to transplantation. It was found that LDLT was a viable option for patients with high Model for End-Stage Liver Disease/Hepatorenal syndrome (MELD/HRS), as they exhibited comparable perioperative outcomes and experienced improved renal recovery.PubMedCrossRef

20.

Berg CL, Gillespie BW, Merion RM, Brown RS Jr, Abecassis MM, Trotter JF, Fisher RA, Freise CE, Ghobrial RM, Shaked A, Fair JH, Everhart JE. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology. 2007;133(6):1806–13 (A.A.S. Group).PubMedCrossRef

21.

Olthoff KM, Smith AR, Abecassis M, Baker T, Emond JC, Berg CL, Beil CA, Burton JR Jr, Fisher RA, Freise CE, Gillespie BW, Grant DR, Humar A, Kam I, Merion RM, Pomfret EA, Samstein B, Shaked A. Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg. 2015;262(3):465–755 (discussion 473-5).PubMedCrossRef

22.•

Tang W, Qiu JG, Cai Y, Cheng L, Du CY. Increased Surgical complications but improved overall survival with adult living donor compared to deceased donor liver transplantation: a systematic review and meta-analysis. Biomed Res Int. 2020;2020:1320830. Thirty-nine studies involving 38563 patients (LDLT n=5531 vs DDLT n=33032) were includedin this meta-analysis, which showed higher biliary and vascular complication rate, but better overall survival in the LDLT group. Importantly, biliary complication rate and overall survival improved as experience increased, while vascular complication rate remained the same, due to the inherent nature of LDLT.PubMedPubMedCentralCrossRef

23.••

Humar A, Ganesh S, Jorgensen D, Tevar A, Ganoza A, Molinari M, Hughes C. Adult Living Donor Versus Deceased Donor Liver Transplant (LDLT Versus DDLT) at a single center: time to change our paradigm for liver transplant. Ann Surg. 2019;270(3):444–51. This single center study from Pittsburgh, including LDLT (n = 245) and DDLT (n = 592) patients, showed that patient survival outcomes were superior in LDLT recipients. Other outcomes demonstrated shorter length of hospital stay, less likelihood of intraoperative blood transfusion, and less likelihood of need for posttransplant dialysis.PubMedCrossRef

24.•

Goto T, Ivanics T, Cattral MS, Reichman T, Ghanekar A, Sapisochin G, McGilvray ID, Sayed B, Lilly L, Bhat M, Selzner M, Selzner N. Superior long-term outcomes of adult living donor liver transplantation: a cumulative Single-Center Cohort Study with 20 years of follow-up. Liver Transpl. 2022;28(5):834–42. This study analyzed the 20‐year outcomes of 668 adults who received LDLT with 1596 DDLTs at Toronto General Hospital. After multivariable adjustment, LDLT and DDLT were associated with a similar hazard of patient and graft survival.PubMedCrossRef

25.

Freise CE, Gillespie BW, Koffron AJ, Lok AS, Pruett TL, Emond JC, Fair JH, Fisher RA, Olthoff KM, Trotter JF, Ghobrial RM, Everhart JE, A.A.S. Group. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant. 2008;8(12):2569–79.PubMedPubMedCentralCrossRef

26.

Woo HY, Lee IS, Chang JH, Youn SB, Bae SH, Choi JY, Chun HJ, You YK, Kim DG, Yoon SK. Outcome of donor biliary complications following living donor liver transplantation. Korean J Intern Med. 2018;33(4):705–15.PubMedPubMedCentralCrossRef

27.

Simoes P, Kesar V, Ahmad J. Spectrum of biliary complications following live donor liver transplantation. World J Hepatol. 2015;7(14):1856–65.PubMedPubMedCentralCrossRef

28.

Hwang S, Lee SG, Sung KB, Park KM, Kim KH, Ahn CS, Lee YJ, Lee SK, Hwang GS, Moon DB, Ha TY, Kim DS, Jung JP, Song GW. Long-term incidence, risk factors, and management of biliary complications after adult living donor liver transplantation. Liver Transpl. 2006;12(5):831–8.PubMedCrossRef

29.

Salvalaggio PR, Whitington PF, Alonso EM, Superina RA. Presence of multiple bile ducts in the liver graft increases the incidence of biliary complications in pediatric liver transplantation. Liver Transpl. 2005;11(2):161–6.PubMedCrossRef

30.

Arikan T, Emek E, Bozkurt B, Mammadov E, Ceyhan O, Sahin T, Dibekoglu C, Serin A, Aydin U, Tokat Y. Does multiple bile duct anastomosis in living donor liver transplantation affect the postoperative biliary complications? Transplant Proc. 2019;51(7):2473–7.PubMedCrossRef

31.

Kollmann D, Goldaracena N, Sapisochin G, Linares I, Selzner N, Hansen BE, Bhat M, Cattral MS, Greig PD, Lilly L, McGilvray ID, Ghanekar A, Grant DR, Selzner M. Living donor liver transplantation using selected grafts with 2 bile ducts compared with 1 bile duct does not impact patient outcome. Liver Transpl. 2018;24(11):1512–22.PubMedCrossRef

32.

Abu-Gazala S, Olthoff KM. Status of adult living donor liver transplantation in the united states: results from the adult-to-adult Living Donor Liver Transplantation Cohort Study. Gastroenterol Clin North Am. 2018;47(2):297–311.PubMedCrossRef

33.

Riddiough GE, Christophi C, Jones RM, Muralidharan V, Perini MV. A systematic review of small for size syndrome after major hepatectomy and liver transplantation. HPB (Oxford). 2020;22(4):487–96.PubMedCrossRef

34.

Broering D, Sturdevant ML, Zidan A. Robotic donor hepatectomy: A major breakthrough in living donor liver transplantation. Am J Transplant. 2022;22(1):14–23.PubMedCrossRef

35.•

Cheah Y, Yang H, Simon CJ, Kim J, Akoad M, Choi G. 130 totally robotic donor hepatectomy: reproducibility of a standardized technique across 2 specialized centers. Am J Transplant. 2022;22:suppl 3. This study represents a large series of robotic living donor hepatectomy in two centers, Demostrating standardized technique can ensure reproducible good results.

36.

Chen PD, Wu CY, Hu RH, Ho CM, Lee PH, Lai HS, Lin MT, Wu YM. Robotic liver donor right hepatectomy: a pure, minimally invasive approach. Liver Transpl. 2016;22(11):1509–18.PubMedCrossRef

37.

Giulianotti PC, Tzvetanov I, Jeon H, Bianco F, Spaggiari M, Oberholzer J, Benedetti E. Robot-assisted right lobe donor hepatectomy. Transpl Int. 2012;25(1):e5-9.PubMedCrossRef

38.

Sanchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L, Heward J, Kerr A, Ali J, Fisher C, Lewis G, Hope A, Kodela E, Lyne M, Farzaneh F, Kordasti S, Rebollo-Mesa I, Jose Lozano J, Safinia N, Heaton N, Lechler R, Martinez-Llordella M, Lombardi G. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. Am J Transplant. 2020;20(4):1125–36.PubMedPubMedCentralCrossRef

39.

Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, Watanabe M, Aoyagi T, Suzuki T, Shimamura T, Kamiyama T, Sato N, Sugita J, Hatanaka K, Bashuda H, Habu S, Demetris AJ, Okumura K. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64(2):632–43.PubMedCrossRef

40.

Sicard A, Lamarche C, Speck M, Wong M, Rosado-Sanchez I, Blois M, Glaichenhaus N, Mojibian M, Levings MK. Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients. Am J Transplant. 2020;20(6):1562–73.PubMedCrossRef

41.

Thomson AW, Humar A, Lakkis FG, Metes DM. Regulatory dendritic cells for promotion of liver transplant operational tolerance: rationale for a clinical trial and accompanying mechanistic studies. Hum Immunol. 2018;79(5):314–21.PubMedCrossRef

Titel: Current Status of Living Donor Liver Transplantation: Impact, Advantages, and Challenges
verfasst von: Hao Liu
Eishan Ashwat
Abhinav Humar
Publikationsdatum: 21.08.2023
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 10/2023
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-023-00882-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of this Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2023

TIPS: indications, Contraindications, and Evaluation

Advances in the Management of Pain in Chronic Pancreatitis

Nutrition in Liver Disease – A Review

Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis

Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice